Pharvaris NV
PHVS23.460USD
-0.320-1.35%
시장 운영 시간 （ET）시세는 15분 지연됩니다
1.28B시가총액
손실P/E TTM
자세한 내용은 Pharvaris NV 회사
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
회사 정보
종목 코드 PHVS
회사 이름Pharvaris NV
상장일Feb 05, 2021
CEOMr. Berndt Modig, CPA
직원 수- -
유형Ordinary Share
회계 연도 종료Feb 05
주소Emmy Noetherweg 2
도시LEIDEN
증권 거래소NASDAQ Global Select Consolidated
국가Netherlands
우편 번호2333 BK
전화31712036410
웹사이트https://pharvaris.com/
종목 코드 PHVS
상장일Feb 05, 2021
CEOMr. Berndt Modig, CPA
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
102.82K
-15.53%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
54.91K
+73.10%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
50.54K
+0.63%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
50.53K
+128.70%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
800.00
--
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Anne Marie De Jonge Schuermans, Ph.D.
Dr. Anne Marie De Jonge Schuermans, Ph.D.
Non-Executive Director
Non-Executive Director
--
--
Mr. Berndt Modig, CPA
Mr. Berndt Modig, CPA
Chief Executive Officer, Co-Founder, Executive Director
Chief Executive Officer, Co-Founder, Executive Director
--
--
Dr. Morgan Conn, Ph.D.
Dr. Morgan Conn, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
102.82K
-15.53%
Ms. Viviane Monges
Ms. Viviane Monges
Non-Executive Director
Non-Executive Director
54.91K
+73.10%
Ms. Anna Nijdam
Ms. Anna Nijdam
Head of Finance, Principal Accounting Officer
Head of Finance, Principal Accounting Officer
50.54K
+0.63%
Dr. Elisabeth Bjork, M.D., Ph.D.
Dr. Elisabeth Bjork, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
50.53K
+128.70%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
800.00
--
Dr. Jochen Knolle, Ph.D.
Dr. Jochen Knolle, Ph.D.
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Co-Founder, Chief Operating Officer, Chief Scientific Officer
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Tue, Aug 19
마지막 업데이트: Tue, Aug 19
주주
주주 유형
주주
주주
비율
General Atlantic LLC
11.76%
Fidelity Management & Research Company LLC
8.47%
Foresite Capital Management, LLC
6.89%
VenBio Partners LLC
6.70%
Viking Global Investors LP
5.70%
기타
60.49%
주주
주주
비율
General Atlantic LLC
11.76%
Fidelity Management & Research Company LLC
8.47%
Foresite Capital Management, LLC
6.89%
VenBio Partners LLC
6.70%
Viking Global Investors LP
5.70%
기타
60.49%
주주 유형
주주
비율
Private Equity
25.72%
Investment Advisor
16.37%
Hedge Fund
14.25%
Venture Capital
13.60%
Investment Advisor/Hedge Fund
6.26%
Individual Investor
5.32%
Research Firm
0.08%
Bank and Trust
0.04%
Pension Fund
0.03%
기타
18.34%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
125
52.21M
81.51%
-1.38M
2025Q1
125
53.89M
99.06%
+200.61K
2024Q4
123
53.45M
98.98%
+218.03K
2024Q3
114
53.86M
99.73%
+1.03M
2024Q2
83
52.08M
96.43%
-141.66K
2024Q1
76
49.63M
98.30%
-831.88K
2023Q4
69
47.76M
94.74%
+8.60M
2023Q3
54
36.05M
91.51%
-2.92M
2023Q2
53
35.78M
91.11%
+3.65M
2023Q1
61
28.67M
84.75%
-3.62M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
General Atlantic LLC
7.53M
13.82%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
5.40M
9.9%
--
--
Mar 31, 2025
Foresite Capital Management, LLC
4.41M
8.09%
+12.70K
+0.29%
Mar 31, 2025
VenBio Partners LLC
4.29M
7.87%
--
--
Mar 31, 2025
Viking Global Investors LP
3.65M
6.7%
--
--
Mar 31, 2025
EQT Life Sciences
3.56M
6.53%
--
--
Apr 01, 2025
Bain Capital Life Sciences Investors, LLC
3.30M
6.06%
--
--
Mar 31, 2025
VR Adviser, LLC
3.11M
5.71%
-107.41K
-3.34%
Mar 31, 2025
Deerfield Management Company, L.P.
2.02M
3.7%
--
--
Mar 31, 2025
Commodore Capital LP
1.91M
3.51%
--
--
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Wed, Aug 6
마지막 업데이트: Wed, Aug 6
이름
비율
Virtus LifeSci Biotech Clinical Trials ETF
0.92%
ALPS Medical Breakthroughs ETF
0.65%
iShares MSCI Netherlands ETF
0.18%
iShares MSCI Europe Small-Cap ETF
0.02%
SPDR S&P International Small Cap ETF
0.02%
iShares MSCI EAFE Small-Cap ETF
0.01%
First Trust IPOX Europe Equity Opportunities ETF
0%
Xtrackers MSCI Eurozone Hedged Eqty ETF
0%
Avantis International Small Cap Equity ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
비율0.92%
ALPS Medical Breakthroughs ETF
비율0.65%
iShares MSCI Netherlands ETF
비율0.18%
iShares MSCI Europe Small-Cap ETF
비율0.02%
SPDR S&P International Small Cap ETF
비율0.02%
iShares MSCI EAFE Small-Cap ETF
비율0.01%
First Trust IPOX Europe Equity Opportunities ETF
비율0%
Xtrackers MSCI Eurozone Hedged Eqty ETF
비율0%
Avantis International Small Cap Equity ETF
비율0%
Fidelity Nasdaq Composite Index ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
